Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06522048
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-07-22
Brief Title:
SJSTEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors ICIs vs Non-ICIs
Sponsor:
None
Organization:
None
Study Overview
Official Title:
SJSTEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors ICIs Versus Non-ICIs in Chinese Patients
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Stevens-Johnson SyndromeToxic Epidermal Necrolysis SJSTEN is a severe adverse drug reaction characterized by extensive skin detachment With the increasing use of immune checkpoint inhibitors ICIs in oncology it is crucial to understand the differences in SJSTEN induced by ICIs compared to other drugs This study aims to compare the clinical manifestations and outcomes of Stevens-Johnson SyndromeToxic Epidermal Necrolysis SJSTEN or other severity of cutaneous adverse events induced by immune checkpoint inhibitors ICIs versus other types of drugs We analyzed differences in clinical characteristics treatment methods outcomes and survival time and quality of life
Detailed Description:
Introduction
Stevens-Johnson SyndromeToxic Epidermal Necrolysis SJSTEN is a severe adverse drug reaction characterized by extensive skin detachment With the increasing use of immune checkpoint inhibitors ICIs in oncology it is crucial to understand the differences in SJSTEN induced by ICIs compared to other drugs This study aims to compare the clinical manifestations and outcomes of Stevens-Johnson SyndromeToxic Epidermal Necrolysis SJSTEN or other severity of cutaneous adverse events induced by immune checkpoint inhibitors ICIs versus other type drugs We analyzed differences in clinical characteristics treatment methods outcomes and survival time and quality of life
Methods
Study Design Retrospective cohort study or cross-sectional study
Participants 60 patients with ICI-induced SJSTEN and 100 to 500 patients with other drug-induced SJSTEN
Data Collection Detailed medical records were reviewed to extract information
Statistical Analysis analysis using appropriate statistical tests eg t-test chi-square test
Results
Present the analysis results highlighting significant differences between the two groups Use tables and graphs to illustrate key findings
Conclusion
We discuss the clinical implications of the findings potential mechanisms underlying the observed differences and the relevance to patient management Summarize the main findings and their significance for clinical practice Emphasize the need for tailored treatment approaches based on the type of drug causing SJSTEN
Stevens-Johnson SyndromeToxic Epidermal Necrolysis SJSTEN is a severe adverse drug reaction characterized by extensive skin detachment With the increasing use of immune checkpoint inhibitors ICIs in oncology it is crucial to understand the differences in SJSTEN induced by ICIs compared to other drugs This study aims to compare the clinical manifestations and outcomes of Stevens-Johnson SyndromeToxic Epidermal Necrolysis SJSTEN or other severity of cutaneous adverse events induced by immune checkpoint inhibitors ICIs versus other type drugs We analyzed differences in clinical characteristics treatment methods outcomes and survival time and quality of life
Methods
Study Design Retrospective cohort study or cross-sectional study
Participants 60 patients with ICI-induced SJSTEN and 100 to 500 patients with other drug-induced SJSTEN
Data Collection Detailed medical records were reviewed to extract information
Statistical Analysis analysis using appropriate statistical tests eg t-test chi-square test
Results
Present the analysis results highlighting significant differences between the two groups Use tables and graphs to illustrate key findings
Conclusion
We discuss the clinical implications of the findings potential mechanisms underlying the observed differences and the relevance to patient management Summarize the main findings and their significance for clinical practice Emphasize the need for tailored treatment approaches based on the type of drug causing SJSTEN
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None